Deaths and cardiovascular events in men receiving testosterone [2]

JAMA

Volumn 311, Issue 9, 2014, Pages 963-964

  Riche, Daniel M ^a   Baker, William L ^b   Koch, Christian A ^c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ANDROGEN THERAPY; BLOOD VISCOSITY; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEMATOCRIT; HUMAN; LETTER; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SLEEP DISORDERED BREATHING; SMOKING; TESTOSTERONE BLOOD LEVEL; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE; ANDROPAUSE; DRUG EFFECT; MALE; NOTE;

ANDROPAUSE; HUMANS; MALE; MYOCARDIAL INFARCTION; STROKE; TESTOSTERONE;

EID: 84895420465     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.386     Document Type: Letter

References (4)

1. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
2. Bhasin S, Cunningham GR, Hayes FJ, et al; Endocrine Society Task Force. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.
3. Wells RE Jr, Merrill EW. Influence of flow properties of blood upon viscosity-hematocrit relationships. J Clin Invest. 1962;41:1591-1598.
4. Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J Sex Med. 2013;10(5):1401-1409.